Standard therapy for pediatric Hodgkin's disease is combined modality treatment, typically COPP/ABVD chemotherapy with 25 Gy of involved-field radiation therapy (IF-RT). Long-term survival results with this therapy are 95% in early stage and 85% in advanced stage disease. Given this excellent outcome, the focus has become how to reduce treatment-related toxicity, specifically late effects of chemotherapy and radiation. This study was started in 1995 by the Children's Cancer Group to investigate whether the superior event-free and overall survival data produced with combined modality regimens could still be achieved with chemotherapy alone in patients who showed complete response to chemotherapy.
Pts < 21 years old with newly diagnosed Hodgkin's disease were enrolled between 1/95 and 12/98.
Clinical staging only
Classified by presence or absence of "B" symptoms (weight loss, fever, night sweats) and "adverse risk factors" as defined by investigators (hilar adenopathy, nodal aggregate with diameter greater than 10 cm, etc)
Three different treatment groups defined based on above classification criteria
Group 1 received COPP/ABV hybrid chemotherapy x 4 cycles every 28 days
Group 2 received COPP/ABV hybrid chemotherapy x 6 cycles every 28 days
Group 3 received intensive multidrug chemotherapy (COPP/ABV, cytarabine, etoposide) x 2 cycles every 63 days
Patients with complete response to chemotherapy (including incomplete radiologic responses but at least 70% reduction in volume) randomized to low dose IF-RT vs. no RT
Low-dose IF-RT given 3 weeks after completing chemotherapy, 21 Gy = 12 fractions of 1.75 Gy each
If Stage IV disease with pulmonary disease, additional 10.5 Gy given to lungs
Primary endpoint of event-free survival (EFS)
Secondary endpoint of overall survival (OS) and post-relapse survival
Accrual goal = 650 pts for 83% power to detect ~6% reduction in EFS at minimum 1 year of follow-up
Primary analysis was intent-to-treat, but data also presented for treatment-received
Randomization stopped prematurely secondary to increased number of relapses on no-RT arm
834 enrolled, 5 ineligible
501 randomized: 251 got RT and 250 no RT
83% complete response
3-yr EFS = 87%
3-yr OS = 95%
3-yr EFS = 92% in RT arm vs. 87% in no RT arm (p=.057)
3-yr OS = 98% in RT arm vs. 99% in no RT arm (p=0.90)
* No significant difference between intent-to-treat and as-treated analyses
*Of note, 30 of the 501 randomized pts switched arms
23 moved from RT to no RT arm, and 5 of these 23 relapsed
7 moved from no RT to RT arm, and none of these relapsed
Median time to relapse in no RT arm = 6 mos, with most relapses occurring in sites of previously known disease
Median time to relapse in RT arm = 14 mos
Acute toxicity generally chemo-related, with higher rates of infectious and GI complications in group 3 pts (more intense chemo) vs. groups 1 and 2
Better EFS with chemotherapy + low-dose involved-field RT compared to chemotherapy alone in pediatric Hodgkins' disease
No OS difference seen yet between RT vs. no RT arms, as authors admit follow-up is not long enough
Although OS is often considered the ultimate goal, the value of EFS should not be neglected. Salvage therapy for relapsed disease is not benign and has a significant effect on quality of life as well as risk of late effects. Preventing a relapse in the first place, ie: improving event-free survival is thus a very significant endpoint.
Modern radiation techniques with low-dose involved fields have decreased treatment-related toxicity compared to standard dose RT.
While late effects and toxicity of chemotherapy are certainly of concern, the use of hybrid regimens has allowed reduction in total exposure to any one single agent, thereby reducing associated single-agent toxicity, all while sustaining efficacy.
Although results of this trial clearly demonstrate a role for radiation in the management of these patients, the authors still suggest the possible existence of a subset of these patients whose likelihood of microscopic residual disease following chemotherapy is low enough to justify exclusion of radiation therapy, ie: risks outweigh any potential benefit.
For now, however, combined modality therapy remains the standard of care.
OncoLink is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through OncoLink should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem or have questions or concerns about the medication that you have been prescribed, you should consult your health care provider.